Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$640 Mln
P/E Ratio
--
P/B Ratio
6.47
Industry P/E
--
Debt to Equity
0.01
ROE
-0.69 %
ROCE
-65.53 %
Div. Yield
0 %
Book Value
0.52
EPS
-0.38
CFO
$-552.86 Mln
EBITDA
$-216.25 Mln
Net Profit
$-1,064.11 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corp (ABUS)
| 0.61 | -2.95 | -0.90 | 19.64 | 8.72 | 22.15 | -15.97 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corp (ABUS)
| 7.30 | -40.10 | 9.58 | 27.70 | -27.42 | -24.04 | 106.12 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 5.44 | 2,010.15 | -- | 4 | |
| 1.41 | 272.20 | -- | -83.54 | |
| 1.80 | 705.73 | 16.36 | 3.8 | |
| 1.49 | 383.37 | -- | -8.08 |
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc,... subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania. Read more
Co-Founder, Interim President, CEO & Director
Mr. Michael J. McElhaugh
Co-Founder, Interim President, CEO & Director
Mr. Michael J. McElhaugh
Headquarters
Warminster, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Arbutus Biopharma Corp (ABUS) stood at $ 132 Mln as on 31-Dec-24
The share price of Arbutus Biopharma Corp (ABUS) is $3.29 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Arbutus Biopharma Corp (ABUS) has given a return of 8.72% in the last 3 years.
Arbutus Biopharma Corp (ABUS) has a market capitalisation of $ 640 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Arbutus Biopharma Corp (ABUS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Arbutus Biopharma Corp (ABUS) and enter the required number of quantities and click on buy to purchase the shares of Arbutus Biopharma Corp (ABUS).
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
The CEO & director of Mr. Michael J. McElhaugh. is Arbutus Biopharma Corp (ABUS), and CFO & Sr. VP is Mr. Michael J. McElhaugh.
There is no promoter pledging in Arbutus Biopharma Corp (ABUS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
279
|
|
|
75
|
|
|
49
|
|
|
45
|
| Arbutus Biopharma Corp (ABUS) | Ratios |
|---|---|
|
Return on equity(%)
|
-68.76
|
|
Operating margin(%)
|
-1130.82
|
|
Net Margin(%)
|
-1133.04
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Arbutus Biopharma Corp (ABUS) was $0 Mln.
$-0.05
(
